Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972).
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 09 Dec 2011 Location (Italy) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Official Title amended as reported by ClinicalTrials.gov.
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.